May 31 Approaching, page-7

Right now the SP is of no concern to UNS, AMGN, or Orbimed. Financing is in place for the next 5 -6 quarters along with other potential notes AMGN can buy and 16MM stock warrants that Orbimed can buy.

I would suspect that they are preparing for a management change. The new management will be announced and then they will get briefed, do a review, and at the next EC in May announce their strategic plan for the future. It could come earlier but that 30 days during April lends credibility that they have thoroughly reviewed the company and designed a plan.

The new management team will start with good will and hopefully they won't squander it. Whatever they present they want to make sure is nailed down so that performance meets expectations. I would suspect that whoever is brought in will have sufficient background in building out manufacturing capabilities along with establishing supply logistics.

If as I have been posting both Lovenox and Hikma are ramping then they will also have good news to present. At this point they damn well need to make sure what they are promising can be delivered and in the time frame promised as well.

IMO UNS is a R&D company moving to being a manufacturing company and experiencing all the growing pains that go along with the struggle.